EUVIMEDEUVIMED entdecken
Crossref

Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: A single-center survey-based study

Xun Feng, Xingli Zhou, Xiwen Zhang, Yue Xiao, Furong Li, Wenyao Mi, Jingya Gao, Jinqiu Wang, Yunqi Zhou, Mingqi Wang, Wen Wang, Wei Li

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xun Feng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Pemphigus, COVID-19, Immunosuppressive Agents, Glucocorticoids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The prevalence and outcomes of coronavirus 2019 (COVID-19) among patients using glucocorticoids and immunosuppressants remain controversial. AIM: The study aims to investigate the impact of immunosuppressants especially glucocorticoids on patients in the Autoimmune Bullous Diseases Cohort of West China Hospital (AIBDWCH) during COVID-19. METHODS: We conducted a cross-sectional survey from December 7, 2022, to February 8, 2023, using questionnaires administered either face-to-face or by phone. COVID-19 cases were classified as confirmed, probable, or suspected according to World Health Organization criteria. Patients were divided into Group A (confirmed and probable cases) and Group B (suspected and other cases). The impact of glucocorticoids and immunosuppressive agents on COVID-19 disease and progression was evaluated with logistic regression models. RESULTS: This study included 111 patients with pemphigus. Overweight patients had a reduced risk of confirmed COVID-19 (odds ratio [OR] 0.35 [95 % CI 0.13-0.97], p = 0.045). Patients treated with a medium dose of prednisone during the pandemic had a lower incidence of COVID-19 compared to those on low doses, though the difference was not statistically significant. No independent effects of age, sex, comorbidities, and therapies were observed. No significant differences were found in COVID-19 symptoms among different therapy groups. CONCLUSIONS: Treatment with immunosuppressants, particularly glucocorticoids at low-to-medium doses, did not elevate COVID-19 risk in pemphigus patients. Consistent outcomes across treatments confirm the safety of these therapies during the pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemphigusCOVID-19Immunosuppressive AgentsGlucocorticoidsHumansMaleFemaleMiddle AgedCross-Sectional StudiesAdultAgedChinaSARS-CoV-2Surveys and QuestionnairesRisk Factors

Stichwörter der Autor:innen

COVID-19GlucocorticoidsImmunosuppressantPemphigusSARS-CoV-2 infection

Substanzen

Immunosuppressive AgentsGlucocorticoids

Autor:innen und Institutionen

  • Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Chinese Evidence-based Medicine Center and Cochrane China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Chinese Evidence-based Medicine Center and Cochrane China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: wangwen83@outlook.com.
  • Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: liweihx_hxyy@scu.edu.cn.

Zitieren

APA

Feng, X., Zhou, X., Zhang, X., Xiao, Y., Li, F., Mi, W., Gao, J., Wang, J., Zhou, Y., Wang, M., Wang, W., & Li, W. (2024). Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: A single-center survey-based study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112307

Vancouver

Feng X, Zhou X, Zhang X, Xiao Y, Li F, Mi W, et al. Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: A single-center survey-based study. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112307

BibTeX
@article{Feng2024,
  author = {Feng, Xun and Zhou, Xingli and Zhang, Xiwen and Xiao, Yue and Li, Furong and Mi, Wenyao and Gao, Jingya and Wang, Jinqiu and Zhou, Yunqi and Wang, Mingqi and Wang, Wen and Li, Wei},
  title = {Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: A single-center survey-based study},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112307}
}
Kostenlos starten →